Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1029 in persistent asthma uncontrolled on montelukast
NCT02720081Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing MK-1029 + Montelukast with Placebo + Montelukast (2 arms). Primary endpoint: Forced Expiratory Volume in One Second at 6 weeks. Started May 2016; status: completed.
02
Drugs
MK-1029
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02720081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02720081.